In the original publication, the values provided for the isoflavone and glucosinolate intake variables were incorrectly labeled in Table 1. The correct values of 6.3 mg/day for isoflavone intake, and 20.4 mg/day and 50.1 mg/day for glucosinolate intake are provided in this erratum. Under the “Statistical Analysis” section, second paragraph, the values in the 11th line “…time since diagnosis (< 4, 3–36, and ≥ 36 months)…” was mislabeled. The correct values were “< 24, 24–36, and > 36 months”.
Table 1.
Population characteristics
| Total population | Non-Hispanic White | Chinese American | |
|---|---|---|---|
|
| |||
| Total N (%) | 365 (100) | 173 (47.4) | 192 (52.6) |
| Age in years (mean, SD) | 57.1 (10.4) | 57.2 (10.5) | 56.9 (10.4) |
| Menopausal status (N, %) | |||
| Premenopause | 47 (13.0) | 21 (12.3) | 26 (13.7) |
| Induced menopause | 61 (16.9) | 30 (17.5) | 31 (16.3) |
| Perimenopause | 81 (22.4) | 35 (20.5) | 46 (24.2) |
| Postmenopause | 172 (47.6) | 85 (49.7) | 87 (45.8) |
| BMI (kg/m2) (mean, SD) | 24.0 (4.4) | 25.2 (5.1) | 22.9 (3.1) |
| Physical activity (N, %)a | |||
| Active | 110 (30.1) | 77 (44.5) | 33 (17.2) |
| Minimally active | 136 (37.3) | 58 (33.5) | 78 (40.6) |
| Inactive | 119 (32.6) | 38 (22.0) | 81 (42.2) |
| Cancer stage (N, %) | |||
| Stage 0 | 110 (30.1) | 64 (37.0) | 46 (24.0) |
| Stage I | 166 (45.4) | 77 (44.5) | 89 (46.4) |
| Stage II | 47 (12.9) | 22 (12.7) | 25 (13.0) |
| Stage III | 42 (11.5) | 10 (5.8) | 32 (16.7) |
| Endocrine therapy (N, %) | |||
| None | 148 (40.8) | 74 (42.8) | 74 (38.5) |
| Tamoxifen | 126 (34.5) | 60 (34.7) | 66 (34.4) |
| Aromatase inhibitor | 91 (24.9) | 39 (22.5) | 52 (27.1) |
| Lumpectomy (N, %) | |||
| No | 141 (38.6) | 59 (34.1) | 82 (42.5) |
| Yes | 224 (61.4) | 114 (65.9) | 110 (57.3) |
| Mastectomy (N, %) | |||
| No | 228 (62.5) | 114 (65.9) | 114 (59.4) |
| Yes | 137 (37.5) | 59 (34.1) | 78 (40.6) |
| Chemotherapy (N, %) | |||
| No | 257 (76.3) | 127 (80.4) | 130 (72.6) |
| Yes | 80 (23.7) | 31 (19.6) | 49 (27.4) |
| Radiation therapy (N, %) | |||
| No | 198 (54.2) | 88 (50.9) | 110 (57.3) |
| Yes | 167 (45.8) | 85 (49.1) | 82 (42.7) |
| Time since diagnosis (N, %) | |||
| < 24 months | 108 (29.6) | 48 (27.7) | 60 (31.3) |
| 24–36 months | 111 (30.4) | 49 (28.3) | 62 (32.3) |
| > 36 months | 146 (40.0) | 76 (43.9) | 70 (36.5) |
| Estrogen receptor (N, %) | |||
| Positive | 227 (62.2) | 109 (63.0) | 118 (61.5) |
| Negative | 49 (13.4) | 19 (11.0) | 30 (15.6) |
| Unknown | 89 (24.4) | 45 (26.0) | 44 (22.9) |
| Progesterone receptor (N, %) | |||
| Positive | 196 (53.7) | 91 (52.6) | 105 (54.7) |
| Negative | 80 (21.9) | 37 (21.4) | 43 (22.4) |
| Unknown | 89 (24.4) | 45 (26.0) | 44 (22.9) |
| HER2 (N, %) | |||
| Positive | 44 (12.1) | 18 (10.4) | 26 (13.5) |
| Negative | 167 (45.8) | 74 (42.8) | 93 (48.4) |
| Unknown | 154 (42.2) | 81 (46.8) | 73 (38.0) |
| Soy products (N, %)b | |||
| No intake | 104 (28.5) | 73 (42.2) | 31 (16.1) |
| > 0–< 24.0 g/day | 131 (35.9) | 65 (37.6) | 66 (34.4) |
| ≥ 24.0 g/day | 130 (35.6) | 35 (20.2) | 95 (49.5) |
| Isoflavones (N, %)b | |||
| No intake | 104 (28.5) | 73 (42.2) | 31 (16.1) |
| >0–< 6.3 mg/day | 129 (35.3) | 62 (35.8) | 67 (34.9) |
| ≥ 6.3 mg/day | 132 (36.2) | 38 (22.0) | 94 (49.0) |
| Cruciferous vegetables (N, %)b | |||
| < 33.0 g/day | 121 (33.2) | 77 (44.5) | 44 (22.9) |
| ≥ 33.0–< 70.8 g/day | 120 (32.9) | 58 (33.5) | 62 (32.3) |
| ≥ 70.8 g/day | 124 (33.9) | 38 (22.0) | 86 (44.8) |
| Glucosinolates (N, %)b | |||
| ≤ 20.4 mg/day | 121 (33.2) | 70 (40.5) | 51 (26.6) |
| > 20.4–< 50.1 mg/ day | 120 (32.9) | 55 (31.8) | 65 (33.9) |
| ≥ 50.1 mg/day | 124 (33.9) | 48 (27.7) | 76 (39.6) |
Active: vigorous physical activity ≥ 3 days/week + ≥ 1500 MET-minutes/week or ≥ 3000 MET-minutes/week engaged in any intensity levels of physical activity; minimally active: < Active cut-points and ≥ 600 MET-minutes/week; inactive: < 600 MET-minutes/week
Tertiles
The authors wish to clarify the description of a prior study by Dorjgochoo et al. (2011) in the discussion section: “an observational study among Chinese survivors found that higher soy food intake (45–47 mg/day) increased hot flashes at 6 or 36 months post-breast cancer diagnosis [16]”. The phrase “higher soy food intake (45–47 mg/day)” should have been “higher soy isoflavone intake (> 62.86 mg/day)”. The Dorjgochoo et al. study was referring to soy isoflavone intake specifically and 45–47 mg/day actually refers to the average daily intake of soy isoflavone. Additionally, the authors stated that the Dorjgochoo et al. study “only assessed hot flashes as menopausal symptom outcome”. It should be clarified that the Dorjgochoo et al. study assessed multiple menopausal symptoms but the current study assessed more.
The clarifications mentioned in this erratum do not influence or modify the results and conclusions reported in the original article.